Aberdeen Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$22.8M Sell
204,699
-24,738
-11% -$2.62M 0.08% 230
2017
Q1
$22.5M Sell
229,437
-34,455
-13% -$3.28M 0.08% 219
2016
Q4
$24.3M Sell
263,892
-16,329
-6% -$1.41M 0.09% 205
2016
Q3
$23.7M Sell
280,221
-1,951
-0.7% -$164K 0.08% 195
2016
Q2
$23M Sell
282,172
-17,029
-6% -$1.3M 0.08% 186
2016
Q1
$21.4M Sell
299,201
-32,893
-10% -$2.21M 0.08% 174
2015
Q4
$20.7M Sell
332,094
-299,166
-47% -$20.1M 0.07% 181
2015
Q3
$38.8M Sell
631,260
-120,084
-16% -$8.39M 0.13% 91
2015
Q2
$54.5M Sell
751,344
-29,419
-4% -$2.17M 0.16% 80
2015
Q1
$60M Sell
780,763
-87,427
-10% -$6.26M 0.16% 79
2014
Q4
$58.2M Sell
868,190
-60,507
-7% -$3.82M 0.15% 78
2014
Q3
$56.4M Buy
928,697
+25,468
+3% +$1.57M 0.12% 96
2014
Q2
$53M Sell
903,229
-6,594,128
-88% -$386M 0.11% 116
2014
Q1
$435M Sell
7,497,357
-132,540
-2% -$7.1M 1.21% 25
2013
Q4
$408M Sell
7,629,897
-3,202,300
-30% -$190M 1.14% 24
2013
Q3
$669M Buy
10,832,197
+310,097
+3% +$18.6M 1.88% 20
2013
Q2
$638M Buy
+10,522,100
New +$627M 2.03% 19

Other funds holding DGX

Aberdeen Asset Management's DGX Position: Q2 2017 in Review

Aberdeen Asset Management reduced its Quest Diagnostics (DGX) stake by 11% in Q2 2017, selling an estimated $2.62M and leaving 204,699 shares worth $22.8M. The position accounts for 0.08% of the portfolio, ranked #230.

Aberdeen Asset Management first reported a position in DGX in Q2 2013 and has held it in 17 quarters since. The position peaked at $669M in Q3 2013. 643 funds tracked by Wall St. Rank hold DGX as of Q2 2017.

  • Aberdeen Asset Management held 204,699 shares of Quest Diagnostics worth $22.8M as of Q2 2017.
  • Aberdeen Asset Management sold 24,738 Quest Diagnostics shares in Q2 2017, an estimated $2.62M.
  • Quest Diagnostics made up 0.08% of Aberdeen Asset Management's portfolio in Q2 2017, its #230 holding.
  • Aberdeen Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 17 quarters since.
  • Aberdeen Asset Management's Quest Diagnostics position peaked at $669M in Q3 2013.
  • 643 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.